Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas

Estimated Time
1.00 hr

Release Date
Oct 14, 2022

Expiration Date
Oct 29, 2023

Activity Description
CAR T-cell therapy is a major advance in the treatment of individuals with non-Hodgkin lymphoma, especially for adult patients with relapsed or refractory large B-cell lymphoma. Several CAR-T therapies are now approved for second-line treatment, and data regarding their efficacy, safety, and real-world outcomes continue to emerge. Collaboration among hematologic oncology clinicians is needed to ensure that appropriate patients are referred for evaluation for CAR-T therapy earlier in their treatment journey, potentially offering them a better chance for lasting remission or even a cure.
During Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas, expert cell therapists and a community oncologist, along with several special guests, will highlight the clinical implications of the most recent data on CAR-T therapy, explore referring clinicians’ misperceptions about access to and logistics associated with therapy, and provide practical tips to help cell therapists collaborate more effectively with referring colleagues to optimize shared care.
This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting. 


Accreditation and Disclosure Information

Target Audience
This CE activity is intended for hematologic oncology clinicians who provide CAR-T therapy for individuals with aggressive B-cell lymphomas.

Educational Objectives
After completing this CE activity, the participant should be better able to:

  • Assess the clinical implications of recent and emerging safety and efficacy data for CAR-T therapies
  • Evaluate the implications of recent and emerging data for referring clinicians
  • Respond to common questions from and misperceptions of referring clinicians
  • Collaborate with the inter-professional team to facilitate logistics and access for referred patients
  • Plan strategies to participate in effective shared care with referring clinicians 

Accreditation, Support and Credit

Joint Accreditation with Commendation logo

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement


  Successful completion of this CME activity, which includes participation in the  evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Support Statement
This CE activity is supported through educational grants from Bristol Myers Squibb and Kite, A Gilead Company.

Educational Parterner Statement 
This activity is jointly provided by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.

EACCME® Credit
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC®) should contact the UEMS (

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.3 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.10 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-110-H01-P
Type of Activity: Knowledge

AAPA Credit Designation Statement

AAPA Logo Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 29, 2023. PAs should only claim credit commensurate with the extent of their participation. 

Interprofessional Continuing Education(IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.


Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Christopher R. Flowers, MD, MS
Division Head ad Interim, Division of Cancer Medicine
Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Advisory Board/Consultant: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Epizyme, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, Seagen, Spectrum.
Research Grant: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY

Research Grant: Actinium Pharmaceuticals, Inc, Amgen Inc., Celgene Corp., Johnson and Johnson, Inc., Miltenyi Biotec, Sanofi, Takeda Pharmaceutical Co.
Advisory Board/Consultant: Actinium Pharmaceuticals, Inc., Amgen Inc., Celgene Corp., Jazz Pharmaceuticals, Inc., Johnson and Johnson, Inc., Kite, Novartis, Sanofi, Takeda Pharmaceutical Co.
Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line           
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA

Advisory Board/Consultant for Daiichi Sankyo and Guardant 360.
Speakers’ Bureau with AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus.
Stock Ownership with Phenomune and xCures.
Independent Contractor for xCures.
Crissy Kus, BSN, RN, BMTCN
Clinical Trial Nurse Navigator
The Leukemia & Lymphoma Society
Rye Brook, NY

Has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.

Rayne H. Rouce, MD, BS 
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX

Advisory Board/Consultant for Novartis Pharmaceuticals Corporation and Pfizer Inc.
Research Grant from Tessa Therapeutics
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and The Leukemia & Lymphoma Society, the joint provider do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Lauren Berger, MPH
The Leukemia & Lymphoma Society
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Nicole Dane via email at

For Physicians, if requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

About this Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters,

Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.